The Acceleration of Diabetic Wound Healing by Low-Intensity Extracorporeal Shockwave Involves in the GSK-3β Pathway

Previous studies have demonstrated that extracorporeal shock wave therapy (ESWT) could accelerate diabetic wound healing and that the inhibition of glycogen synthase kinase-3 beta (GSK-3 beta) is involved in epithelial differentiation during wound healing. This study investigated whether the enhancement of diabetic wound healing by ESWT is associated with the GSK-3 beta-mediated Wnt/beta-catenin signaling pathway. A dorsal skin wounding defect model using streptozotocin-induced diabetic rodents was established. Rats were divided into 4 groups: group 1, normal controls without diabetes; group 2, diabetic controls without treatment; group 3, diabetic rats receiving ESWT; and group 4, rats receiving 6-bromoindirubin-3 ' oxime (BIO), a GSK-3 beta inhibitor, to trigger Wnt/beta-catenin signaling. Tissue samples were collected and analyzed by immunohistochemical (IHC) staining and quantitative RT-PCR. The ESWT and BIO-treated groups both exhibited significant promotion of wound healing compared to the healing in controls without treatment. RT-PCR analysis of Wnt-1, -3a, -4, -5a, and -10 and beta-catenin expression showed significantly increased expression in the ESWT group. The IHC staining showed that Wnt-3a and -5a and beta-catenin levels were significantly increased in the ESWT and BIO treatment groups compared to the control groups. ESWT enhancement of diabetic wound healing is associated with modulation of the GSK-3 beta-mediated Wnt/beta-catenin signaling pathway.

Automated summary

This study demonstrated that both ESWT and BIO treatment significantly promoted diabetic wound healing and were associated with the GSK-3 beta-mediated Wnt/beta-catenin signaling pathway.